+ Watch IBB
on My Watchlist
Exchange Traded Funds
Biotech is a safety net for now until energy cost catches up to demand,
Bio tech will continue to lead the market
This is my signal to start focusing on a shorting strategy. The biobubble will not go on forever (though it could take another year or two).
I love Biotech...I just don't know enough about individual companies to invest in one confidently. So, a basket ETF is lovely.
Biotechs are strong this year.
Playing individual biotech stocks is risky business. This is probably the least risky way to play the sector without taking a chance of waking up one morning to see the company's drug was rejected and opens down 50%+ on an FDA rejection.
Price action here just looks off.
My choices in Biotech are an absolute disaster. Nonetheless, I realize that the sector has some wonderful successes and the needs of the boomer generation plus some "newly discovered" illnesses require new medicines. That makes Biotech a sector to have a presence in.Porte is our resident expert in this area and I am choosing this at his suggestion. It is worth noting that the only Biotech firms that have ever rewarded me - on CAPS or RL - are the ones that Porte has suggested to me. His suggestions are enough for me to add this to CAPS if not to add RL funds to.
The age is finally right
Betting to outperform the 500 this leg down.
loading up on biotech
I don't dislike biotech (alliterative double negative for you). However, I am willing to say that there are more bad biotech companies than good. Unfortunately, an ETF is going to have both the good and the bad so I'm going to say that a better way to play the industry is to do some extra research and find out what's actually going to work (though I may have an advantage here cuz I'm living on a campus where some of the best biotech research is being conducted)
Biotech poised for excellent returns when the market rebounds
3 to 5 star stock in one year.
new company, exciting stuff
Biotech - if you're in the field you know what's coming out in the next 3 years. 3-6 years looks even more promising. And there are thousands of studies in the 10-15 year period that are just beginning. We have no idea but in about two years, this EFT will shoot far above the S&P 500.
if you play the bioteh, you got to pick the index
With health care progressing towards personalized medicines, modular diagnosis and such advanced areas, its is only natural to assume that biotech companies will be making the hay while the sun shines. Contrary to expectations the year 2006 brought in mixed results for biotech firms with returns swinging wildly in either direction.The ishare Nasdaq Biotechnology index fund (IBB) maintains a diverse portfolio of about 169 biotech companies, all of which are listed in the Nasdaq stock exchange and the fund tracks the Nasdaq biotechnology index. Of all the companies in the fund except Amgen, which contribute 14% of the total asset share, none of constituents contribute more than 5% of asset share. Also among all other biotechnology funds, IBB charges the least in terms of management fee with 0.48% against an average of 1.5%.The composition of the fund is made up of small cap firms whose fortunes are invariable tied to the success/ failure of a few marketable products that are not yet available. The year 2006 was not too good as Amgen; the fund’s main constituent dropped by 11% thus bringing down the fund’s annual return for the year ended December 31 2006 to 0.57%. The year 2007 is expected to see a spate of new product launches which should prop up the industry.Thus a firm with product launches in 2007 ought to have a good year, however there is one catch. Biotech firms hoping to make the cut will have to find justifications for the complexity involved to educate their patients, to spend exorbitant amount of money for a seemingly small patient population, and high expense of a biotech drug compared to a traditional medicine. Only firms will a sound business model and deep pockets will be able to survive the initial onslaught and rake in revenues even if they manage to bring in new drugs to market. Most of the firm’s in the fund IBB does not fall into this category and thus will not be able to capitalize on the emerging opportunity in Biotech sector.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions